The 411 on TCGA: Share ‘Omics’ Data for Precision Oncology

Video
Conference|American Association for Cancer Research Annual Meeting (AACR)

In this video, Dr. Jean Zenklusen describes an NCI tool that enables researchers, clinicians, and patients to access an array of cancer-related data.

In this video, Dr. Jean Zenklusen describes an NCI tool that enables researchers, clinicians, and patients to access an array of cancer-related data.

Recent Videos
It can cause thrombocytopenia and diarrhea, which are generally manageable and not too big a deal.
Related Content
The rate of MRD negativity, defined as next-generation flow with a sensitivity of 10-5, at the end of consolidation was 74.8%.

Isa-KRd Yields Significant MRD Negativity in High-Risk NDMM Cytogenetic Subgroups

Tim Cortese
September 18th 2025
Article

MRD-negative remission was achieved in 74.8% of all patients with newly diagnosed multiple myeloma treated with isatuximab, carfilzomib, lenalidomide, and dexamethasone.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Responses observed with the elranatamab-based regimen in the MagnetisMM-6 trial are anticipated to deepen with longer follow-up.

Elranatamab Combo Yields Early Efficacy in Transplant-Ineligible NDMM

Russ Conroy
September 17th 2025
Article

Responses observed with the elranatamab-based regimen in the MagnetisMM-6 trial are anticipated to deepen with longer follow-up.

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
July 28th 2025
Podcast

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

A statistically significant difference was observed between the 2 groups in patients who received second-line therapy.

Cisplatin/Carboplatin Plus Etoposide Yield Similar Real-World Efficacy in ES-SCLC

Tim Cortese
September 16th 2025
Article

Cisplatin/etoposide and carboplatin/etoposide achieved median OSs of 8.8 months and 7.8 months, respectively, in those with extensive-stage small cell lung cancer.

Data from the IDeate-Lung01 trial support the potential role that ifinatamab deruxtecan may play in the management of extensive-stage small cell lung cancer.

I-DXd Shows “Impressive” Responses in Extensive-Stage SCLC

Russ Conroy
September 15th 2025
Article

Data from the IDeate-Lung01 trial support the potential role that ifinatamab deruxtecan may play in the management of extensive-stage small cell lung cancer.